Details of the Drug

General Information of Drug (ID: DM4PVDY)

Drug Name
Durvalumab
Indication
Disease Entry ICD 11 Status REF
Urothelial carcinoma 2C92.0 Approved [1]
Hepatocellular carcinoma 2C12.02 Phase 3 [2]
Biliary tract cancer 2C17 Phase 2 [2]
Melanoma 2C30 Phase 2 [2]
Pancreatic ductal carcinoma 2C10.0 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Diffuse large B-cell lymphoma 2A81 Phase 1 [2]
⏷ Show the Full List of Indication(s)
Drug Type
Monoclonal antibody
Sequence
>heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYY
VDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVS
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSRE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
>light chain
EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIP
DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFP
PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL
TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Clearance
The clearance of drug is 8.2 mL/h [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 days [3]
Metabolism
The drug is metabolized via reticuloedothelial system or target-mediated disposition [4]
Vd
The volume of distribution (Vd) of drug is 5.64 L [3]
Cross-matching ID
DrugBank ID
DB11714
TTD ID
D0LS9E
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Modulator [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Urothelial carcinoma
ICD Disease Classification 2C92.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Durvalumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Durvalumab and Siponimod. Multiple sclerosis [8A40] [6]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Durvalumab and Ocrelizumab. Multiple sclerosis [8A40] [7]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Durvalumab and Ozanimod. Multiple sclerosis [8A40] [8]
Deflazacort DMV0RNS Moderate Additive immunosuppressive effects by the combination of Durvalumab and Deflazacort. Muscular dystrophy [8C70] [9]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use
4 European Medicines Agency: IMFINZI (durvalumab) Summary of Product Characteristics
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".